Is CRISPR Therapeutics Stock a Buy?
CRISPR Therapeutics (NASDAQ: CRSP) may be one of the best biotechnology stocks to own in 2020. It's one of a few companies leading the way in gene-editing therapies, a market that the analysts at MarketsandMarkets expect will be worth $11.2 billion by 2025.
CRISPR's shares are up about 50% year to date, propelled by positive developments within its pipeline. The stock is outpacing both the iShares Nasdaq Biotechnology ETF and S&P 500 by a wide margin, and looks positioned to charge higher over the long term. The company leads other gene-editing companies in the hematology space and offers a novel treatment in the immuno-oncology space with plenty of catalysts that could propel the stock over the next 12 months.
Let's take a closer look at CRISPR's portfolio, its position in the competitive landscape, and its current valuation to determine if its stock is a buy today.
Source Fool.com
